Interferon-lambda (IFNL) germline variations and their significance for HCC and PDAC progression: an analysis of The Cancer Genome Atlas (TCGA) data

Table 3 Uni- and multivariate Cox proportional-hazard analyses for disease progression in PDAC patients

Disease progression criteria	Univariate analysis		Multivariate analysis		Schoenfeld residuals
Disease progression criteria	HR (95% CI)	p-value	HR (95% CI)	p-value	p-value
^aLenghth of the specific PFI
Age	1.01 (0.99–1.03)	0.27	–	–	–
Gender (m/f)	1.13 (0.75–1.70)	0.56	–	–	–
Tumor grade (G1 vs. G2)	0.63 (0.33–1.20)	0.16	0.99 (0.51–1.90)	0.97	0.24
Tumor grade (G3/G4 vs. G2)	1.57 (1.01–2.45)	0.05*	1.34 (0.85–2.12)	0.20	0.24
Tumor stage (stage I vs. stage II)	0.32 (0.14–0.74)	0.01*	0.37 (0.15–0.89)	0.03*	0.05
Tumor stage (stage III/ IV vs. stage II)	0.99 (0.46–2.16)	0.98	1.09 (0.50–2.39)	0.83	0.05
IFNL3 rs28416813 genotype (CG/GG vs. CC)	0.60 (0.40–0.91)	0.02*	0.61 (0.40–0.93)	0.02*	0.60
^aOS time
Age	1.03 (1.01–1.05)	0.01*	1.01 (1.00–1.04)	0.13	0.67
Gender (m/f)	1.26 (0.83–1.93)	0.28	–	–	–
Tumor grade (G1 vs. G2)	0.76 (0.24–1.00)	0.05*	0.76 (0.36–1.60)	0.47	0.24
Tumor grade (G3/G4 vs. G2)	1.35 (0.85–2.13)	0.20	1.13 (0.70–1.81)	0.61	0.24
Tumor stage (stage I vs. stage II)	0.37 (0.16–0.86)	0.02*	0.40 (0.16–1.04)	0.06(*)	0.01
Tumor stage (stage III/ IV vs. stage II)	0.90 (0.36–2.23)	0.82	0.95 (0.38–2.40)	0.92	0.01
IFNL3 rs28416813 genotype (CG/GG vs. CC)	0.66 (0.43–1.00)	0.05*	0.68 (0.44–1.07)	0.09(*)	0.66

^a Cox regression analyses were performed for complete data sets (n = 158)
* significant p-value (p ≤ 0.5)
(*) tendency to significant p-value (p ≤ 0.1)
Results with a 95% CI including 1 and/or a significant Schoenfeld residual have to be considered with reservation.

ISSN: 1471-2407